Image: Shutterstock

NOME Important to BioIndustry Growth

Nordic Mentor Network for Entrepreneurship (NOME) will be an important piece of the puzzle if Norway is going to fulfill their ambitions set by the coming White Paper on the Healthcare Industry. If we are to make our bioindustry more competitive and take a leading European role within eHealth, we need to learn from the […]

Image: Shutterstock.

Precision Medicine has a New Target

Researchers at the Centre for Cancer Biomedicine, a Center of Excellence and a member of Oslo Cancer Cluster, have discovered an enzyme wreaking havoc inside cells that turns into tumors. For our body to work as normal, cells need to know which way is up. When cells lose track of their orientation, they can start […]

Illustration: Oslo Cancer Society

Raising Prostate Cancer Awareness

This week on Monday, Prostate Cancer Day, the Norwegian Cancer Society initiated their Blue-Ribbon Campaign to raise prostate cancer awareness. In line with the campaign, Oslo Cancer Cluster gives you the chance to update yourselves on prostate cancer research Thursday the 30th of November.   The Blue-Ribbon campaign is initially a month’s focus on prostate […]

Øyvind Arnesen, Ultimovacs. Photo: Oslo Cancer Cluster

New Funds for Ultimovacs

Investors are recognizing the huge potential of Oslo Cancer Cluster member Ultimovacs. They are currently investing an additional 125 million NOK in the cancer research company.   Well known investors and Ultimovacs backers Stein Erik Hagen, Anders Wilhelmsen og Bjørn Rune Gjelsten are among financiers putting fresh money into the cancer research company, according to […]

Image illustration: Shutterstock

Photocure with FDA Priority

Oslo Cancer Cluster member Photucure recently announced that the U.S. Food and Drug Administration (FDA) has accepted a Priority Review for an expansion of Cysview.   The FDA has accepted a supplemental New Drug Application (NDA) for Cysview on a priority review basis. Photocure, the Oslo, Norway-based company that developed and is marketing the drug-device […]